Back to Search
Start Over
Systematic Review of the Evolution of Health‐Economic Evaluation Models of Osteoarthritis.
- Source :
- Arthritis Care & Research; Nov2021, Vol. 73 Issue 11, p1617-1627, 11p
- Publication Year :
- 2021
-
Abstract
- Objective: To comprehensively synthesize the evolution of health‐economic evaluation models (HEEMs) of all osteoarthritis (OA) interventions, including preventions, core treatments, adjunct nonpharmacologic interventions, pharmacologic interventions, and surgical treatments. Methods: The literature was searched within health‐economic/biomedical databases. Data extracted included OA type, population characteristics, model setting/type/events, study perspective, and comparators; the reporting quality of the studies was also assessed. The review protocol was registered at the International Prospective Register of Systematic Reviews (CRD42018092937). Results: Eighty‐eight studies were included. Pharmacologic and surgical interventions were the focus in 51% and 44% of studies, respectively. Twenty‐four studies adopted a societal perspective (with increasing popularity after 2013), but most (63%) did not include indirect costs. Quality‐adjusted life years was the most popular outcome measure since 2008. Markov models were used by 62% of studies, with increasing popularity since 2008. Until 2010, most studies used short‐to‐medium time horizons; subsequently, a lifetime horizon became popular. A total of 86% of studies reported discount rates (predominantly between 3% and 5%). Studies published after 2002 had a better coverage of OA‐related adverse events (AEs). Reporting quality significantly improved after 2001. Conclusion: OA HEEMs have evolved and improved substantially over time, with the focus shifting from short‐to‐medium‐term pharmacologic decision‐tree models to surgical‐focused lifetime Markov models. Indirect costs of OA are frequently not considered, despite using a societal perspective. There was a lack of reporting sensitivity of model outcome to input parameters, including discount rate, OA definition, and population parameters. While the coverage of OA‐related AEs has improved over time, it is still not comprehensive. [ABSTRACT FROM AUTHOR]
- Subjects :
- OSTEOARTHRITIS
PHARMACOLOGY
ARTHRITIS
ADVERSE health care events
MEDICAL economics
Subjects
Details
- Language :
- English
- ISSN :
- 2151464X
- Volume :
- 73
- Issue :
- 11
- Database :
- Complementary Index
- Journal :
- Arthritis Care & Research
- Publication Type :
- Academic Journal
- Accession number :
- 153383547
- Full Text :
- https://doi.org/10.1002/acr.24410